Sanofi’s JAK2 Inhibitor Meets Primary Endpoint in Late-Stage Trial for Treatment of Myelofibrosis
Today, Sanofi announced that its JAK2 inhibitor met the primary endpoint in both dose groups during a Phase III study evaluating the drug for treatment of myelofibrosis.
The pivotal study, JAKARTA, evaluated once-daily, oral SAR302503 compared to placebo. The study consisted of 289 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, which were randomly assigned a 400mg dose of SAR302503, 500mg dose of SAR302503, or placebo for 24 weeks. The primary endpoint was the proportion of patients with a reduction in spleen volume ≥ 35 percent after 24 weeks of treatment. According to the company, the primary endpoint was met and full results will be presented at an upcoming medical congress.
“Patients with myelofibrosis in advanced stages are desperately ill and in need of treatments that will improve their outcomes. I…
View original post 150 more words
A simple and general approach for the synthesis of highly functionalized 6-oxo-1,6-dihydropyridines
Journal title: Tetrahedron
author: Dr. Abraham Thomas First author: Dr. Sukeerthi Kumar
Apr 22, 2013 – A simple and general approach for the synthesis of highly functionalized 6-oxo-1, 6-dihydropyridines. Sukeerthi Kumar,; Rajni R. Thakur, …